testis as an example, our strategies identified 298 genes annotated as expressed in the fetal testis. We cross-referenced these genes to existing microarray data and narrowed the list down to cell-type-specific candidates (35 for Sertoli cells, 11 for Leydig cells, and 25 for germ cells). Our strategies can be customized so that they allow researchers to effectively and confidently prioritize genes for functional analysis. The process of sex determination is complex, involving multiple pathways that shape the identity of the gonads. Identifying the genes that make up these pathways is like solving a complex puzzle. We propose that by using public databases investigators can efficiently identify new candidate genes for their involvement in gonadogenesis. While scientists have gathered a number of missing puzzle pieces, unexplained cases of disorders of sexual development (DSD) and infertility clearly indicate that many key pathways have not yet been placed in the picture [Ono and Harley, 2013] . In order to fill in the missing pieces, mouse models were used to generate numerous transcriptomic studies that reveal variations in gene expression between sexes, cell types, developmental stages, and different genotypes [Albrecht and Eicher, 2001 ; Nef Keywords Candidate gene · Databases · Data mining · Enrichment · Expression atlas · Gene prioritization · GO terms · Knowledgebases · Ontology · Ovary · Sex determination · Testis · Transcriptomics Abstract With each new microarray or RNA-seq experiment, massive quantities of transcriptomic information are generated with the purpose to produce a list of candidate genes for functional analyses. Yet an effective strategy remains elusive to prioritize the genes on these candidate lists. In this review, we outline a priori tizing strategy by taking a step back from the bench and leveraging the rich range of public databases. This in silico approach provides an economical, less biased, and more effective solution. We discuss the publicly available online resources that can be used to answer a range of questions about a gene. Is the gene of interest expressed in the system of interest (using expression databases)? Where else is this gene expressed (using added-value transcriptomic resources)? What pathways and processes is the gene involved in (using enriched gene pathway analysis and mouse knockout databases)? Is this gene correlated with human diseases (using human disease variant databases)? Using mouse fetal
. Each of these studies had the goal to identify new genes that control key processes in sex determination of the gonads.
Over time the strategies used to generate new candidate genes have changed with the availability of different technologies. Initial cDNA array screens in the 1990s and early 2000s compared male and female gonads to search for genes enriched in either testis or ovary, with the assumption that enriched genes in one sex were important for development of that fate [Bowles et al., 2000; Wertz and Herrmann, 2000; McClive et al., 2002; Menke and Page, 2002] . With the advent of microarrays, comparing gene expression between multiple groups, such as testis and ovary at different developmental time-points, became feasible. This approach allowed the identification of genes that were expressed at key developmental timepoints and begun the process of fitting them together in pathways that were initiated by marshaling transcription factors such as SOX9 [Grimmond et al., 2000; Nef et al., 2005; Coveney et al., 2008; Munger et al., 2009; Bouma et al., 2010] . Subsequently, to move beyond male and female comparisons and to gain more cell type-specific information, scientists generated transcriptomic data from enriched cell populations isolated from cell type-specific reporter mice. This strategy was used to isolate somatic cells (Sertoli, Leydig, and others) and germ cells to identify key differences between lineages in addition to sexes [Nef et al., 2005; Beverdam and Koopman, 2006; Bouma et al., 2007; Rolland et al., 2011; McClelland et al., 2015; Inoue et al., 2016] . This approach was used in the GUDMAP (GenitoUrinary Development Molecular Anatomy Project) Consortium-backed microarray of 4 key cell types (supporting, germ, interstitial, and endothelial cells), aiming at differences in cell population gene expression over a developmental time course [Jameson et al., 2012] . Over the past 2 decades, transcriptomic studies identified numerous factors and sex-linked genes that are critical for gonadogenesis. Efforts by other groups continued to fill in the puzzle with the advent of RNA-seq and whole exome sequencing. RNA-seq allows gene expression to be assayed at a greater sensitivity in a more unbiased way than microarrays on whole gonads and sorted cells [Lindeman et al., 2015; McClelland et al., 2015; Inoue et al., 2016] . In tandem, the decreasing cost for next-generation sequencing has made whole exome sequencing of DSD patients economically feasible [Ono and Harley, 2013 ; for review see Ostrer, 2014; Eggers et al., 2016] . The function of genes, identified from mutations in DSD patients, can then be confirmed in the mouse model in complete knockouts or exact recapitulations of the mutated human gene. One common feature of these approaches is that they produce an extensive list of candidate genes. The key question then becomes: how do we prioritize the list of candidate genes and determine which ones to pursue for further functional analyses?
Although the way we identify candidate genes continues to evolve, the way in which we prioritize them for further functional analysis remains rudimentary; the most obvious candidates were selected based on whether they fit into existing pathways with known roles in gonadogenesis. From experience we know that transcription factors or sex chromosome-linked genes are good candidates for functional analyses. Traditionally, scientists tried to prioritize genes by targeting them with a sexually dimorphic expression pattern, profiling gene expression over a developmental time course, and then performing in situ hybridization or immunohistochemistry on the cell type in which the gene is expressed [Menke and Page, 2002; McClive et al., 2003; Bouma et al., 2004; Rolland et al., 2011] . The gene with the most robust sex-specific expression, the best working in situ hybridization probe (or antibody), and some background information in PubMed comes forward as the candidate gene. This prioritization problem is not new: genes identified in early cDNA screens were present in subsequent microarrays and were found to be critical for gonadogenesis [20] [21] [22] [23] [24] [25] years after their identification. The problem was not the identification of these genes, the issue was to prioritize them or identify them as good candidates for further functional analysis. Confronted by a list that contains hundreds of genes, the 'gene prioritization problem' looms bigger than ever. We argue that current methods of selecting a candidate gene are unnecessarily expensive, ineffective, and biased in today's information rich world. We propose that the community could better prioritize genes for functional validation by utilizing publically available gene expression and transcriptomic databases. These resources represent a valuable pool of information that can be used freely by any scientist to move projects and hypotheses forward.
In this review, we discuss the development and use of gene ontology (GO) terms by databases and the key features of a 'good' gene list before describing 4 key resources: expression atlases and databases, added-value transcriptomic databases, pathway or GO term enrichment analysis, and mouse knockout or human disease variant databases. We describe how to utilize these databases to prioritize genes and discuss the strengths and limitations of each resource. Finally, we demonstrate how to use these resources as a discovery tool.
As an example, we analyze 'testis' annotated genes in the Eurexpress expression database. Although the reanalysis of existing data sets and in silico discovery is still a fairly new concept in the field of sex determination, we argue that by capitalizing on the wide range of publically available databases, scientists can prioritize genes in a candidate list without exhausting research dollars and time chasing ghosts.
Online Tools for Generating and Analyzing the Genes-Of-Interest List
While enormous amounts of functional data are available in the published literature, each paper typically reports on a limited number of genes and developmental stages. However, there are numerous publically available databases that host a wide range of expression and transcriptomic data covering murine embryonic development. To increase the utility of individual databases, most core databases are linked with specialist databases to create ways to springboard between resources. For example, Mouse Genome Informatics (MGI; http://www.informatics.jax.org/) ( Table 1 ) provides a comprehensive data page linking to most major resources for each gene. However, it is not yet possible to perform a bulk query and retrieve a set of metrics or a list of genes from a core database. How the user implements the strategies outlined in this paper will depend on the nature of the question and what types of data are used. If the investigator has already had data from a patient or mouse model, prioritizing genes by focusing on key biological processes or signaling pathways might be the first step. Conversely, if investigators are searching for new candidates, then reanalyzing published transcriptomic data may provide new genes of interest, followed by validating the expression patterns in the existing expression databases. In this section, we aim to guide investigators through how each type of database works and what can be gained from each one so they can customize their search to solve their 'gene prioritization problem'.
The Construction of a GO Framework
The GO framework [Ashburner et al., 2000] is an example of a flexible and rapidly developing textual framework for the molecular functions of gene products, including their subcellular localization, the biological processes in which they function, and the processes in which they participate during embryogenesis. The GO Consortium (http://geneontology.org/) ( Table 1 ) , initially a collaboration between the Mouse Genome Informatics, FlyBase, and Saccharomyces Genome databases, was formed to create descriptions of biological processes and establish standards for the community-wide organization of a set of frameworks in order to enable the integration of data from different model organisms [FlyBase Consortium, 1999; Ashburner et al., 2000; Ball et al., 2000; Blake et al., 2000; Ringwald et al., 2000] . The structured language laid out by the Gene Ontology Consortium to describe the properties of gene products are called GO terms. GO terms are catalogued in a central thesaurus hosted by the GO Consortium (http://geneontology.org/ page/ontology-documentation) ( Table 1 ). Databases using GO terms have these terms as set outputs (or answers). Therefore, it is important to understand how GO frameworks are constructed, what the limitations of GO terms are, and how GO terms are utilized by different databases.
There are 3 central themes defined by GO terms based on the function of the protein: (1) terms that describe the Cellular Component , the parts of a cell or its extracellular environment; (2) terms that describe the Molecular Function , the basic functions of a gene product at the molecular level; and (3) terms that describe Biological Process , which is defined as the molecular events necessary for the function of cells, tissues, organs, and organisms [Ashburner et al., 2000] . Within the ontology framework, each term has defined relationships to one or more other terms in the same classification and sometimes to terms in other classifications. Some terms are parent terms to a host of more specific terms like a branching tree to describe things in greater and greater detail. For an example of GO annotation, the gene product 'Sox9' can be described by the Molecular Function term 'transcription', the Biological Process terms 'cell differentiation' and 'system development', and the Cellular Component term 'nucleus'. To look up terms for specific genes, a brief overview can be found in the Gene Ontology Classifications section of MGI and more detail can be obtained by querying AmiGO2 (http:// amigo.geneontology.org/amigo/landing) ( Table 1 ) .
The consistent use of GO terms for cellular and biological processes and for anatomical structures throughout development is essential for the success, development, and maintenance of biological databases. Creating and maintaining ontologies seem straightforward; however, the creation and maintenance of ontologies in the context of developmental biology poses some interesting problems. The subtleties between different ontology [
cell type] cell fate specification
The process whereby a cell becomes capable of differentiating autonomously into a [cell type] cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.
[
cell type] cell fate determination
The process whereby a cell becomes capable of differentiating autonomously into a [cell type] cell regardless of its environment. Upon determination, the cell fate cannot be reversed.
Each of these terms, although similar on first glance, encapsulates important information about the cell and the process that takes place, and they are not interchangeable. Knowing what pertinent GO terms mean in detail and how those GO terms are nested within other GO terms is critical to extract important information about the function of a gene product.
GO terms can be a powerful tool to describe biology and make findings accessible across data formats and platforms. The core item the investigator needs to begin is a 'good' candidate gene list, but what defines a 'good' list?
Key Features of a 'Good' Candidate Gene List
Lists of 'interesting' genes, which may range in size from hundreds to thousands of genes, can reveal patterns, signaling cascades, and processes important for organogenesis. The analysis of these data sets has gradually become the responsibility of the biologist rather than the bioinformatician, as more biologist-friendly tools become available. In addition to analyzing new primary data, reanalysis and inclusion of published data should be considered to bolster a new analysis. Before considering how to analyze the genes-of-interest list, the quality of the list itself should be assessed. Realistically, any correlations and directions indicated by a list should be confirmed by bench work and functional analysis. Regardless of this, as a general rule a 'good' gene list has a few key features [modified from Huang et al., 2009a] : (1) a reasonable number of biological (not technical) replicates and the reproducibility of the list before analysis, either from independent experiments or by statistical testing (appropriate p values and test parameter should be chosen for each experiment), are important considerations, especially when re-analyzing data; (2) the genes-of-interest list contains a series (not just 1 or 2 bona fide marker genes (i.e., Sox9, Amh, and Dhh for the fetal testis) that would be expected as a result for the given experiment or analysis. When looking at reprocessed data, it is important to remember that the statistical approaches for microarray and RNA-seq analysis have changed over time. This is especially important when processing data from pre-2012. Simple reprocessing of experiments using newer analysis methodology may result in subtle or more dramatic changes in the final genes-of-interest list compared to the original analysis. If using reprocessed data, checking for known marker genes remains a simple, yet effective metric to determine if the analysis and data is clean; and (3) the number of genes on the list is big enough for pathway analysis (around 100 genes) but not so big that it is not comparable (around 2,000-3,000 genes). The size of a list can affect the ontologies that are selected for, especially for smaller lists. As a test, the enriched terms should appear in the queried list and not in a random list of approximately the same size (number of genes).
Expression Atlases and Databases
The first question the investigator often asks is in which cell type/s a gene is expressed during gonadogenesis. In the past, in situ hybridization on embryonic gonads was used to validate the expression of candidate genes from mRNA expression studies and to determine in which cell type the gene was expressed. This first pass analysis should now be considered redundant for many developmental biologists with the completion of largescale in situ hybridization atlases that aim to capture gene expression throughout the murine embryo on a gene-bygene basis. Several databases used high-throughput ro-botic technology to conduct RNA in situ hybridization on sectioned or whole murine tissues [Geffers et al., 2012] . The consortiums then manually mapped and annotated gene expression patterns on standardized images using anatomical GO terms ( Fig. 1 A) [Gitton et al., 2002; Reymond et al., 2002; Visel et al., 2004] . These databases can play a critical role in validation of the quality of a gene list, taking an in-depth look at many genes in a list with a focus on a specific process or pathway, or can be used as a discovery tool to uncover new candidate genes and expression patterns (see Using Databases as a Discovery Tool to Construct a Genes-Of-Interest List for Testis Development).
In the race to map the expression pattern to the transcriptome throughout development, specialized knowledgebases, such as the Allen Brain Atlas (ABA; http:// brain-map.org/) [Lein et al., 2007; Jones et al., 2009] , which catalogues gene expression in brain sections throughout development and adulthood, have developed alongside with more general whole embryo atlases, such ( Table 2 ) . Specialized databases cataloguing expression of genes in specific murine tissues such as the ABA, the Gene Expression Nervous System Atlas (GENSAT; http://www.gensat.org/; the nervous system) [Gong et al., 2003] , the GenitoUrinary Development Molecular Anatomy Project (GUDMAP; the gonads, reproductive tract, kidney and urinary tract) [Brunskill et al., 2008] , and FaceBase (https://www.facebase.org; curated craniofacial data from mouse, human, and zebrafish) [Van Otterloo et al., 2016] have now been integrated into broader databases. These collaborations bring together specialist expression data with that from projects on the whole embryo such as the Edinburgh Mouse Atlas of Gene Expression (EMAGE; http://www.emouseatlas.org/ emage/) [Hill et al., 2004] Hayamizu et al., 2015] .
As an example database, the Eurexpress transcriptome atlas catalogues annotated RNA in situ hybridization expression patterns for approximately 18,000 Mus musculus protein-coding genes at 14.5 days post coitus (dpc). Using Eurexpress sections taken throughout the entire embryo, annotated gene expression patterns can be visualized in an online viewer. This atlas aims to achieve complete representation of all embryonic tissues throughout the 24 representative sagittal sections . For example, the gene Star is expressed in the adrenal and fetal Leydig cells at 14.5 dpc; in the Eurexpress assay it is annotated as expressed in the testis on section 5-8 and 14-16. Flipping through the online slide deck and zooming in, expression of Star is clearly detected in the adrenal and testis in section 6 ( Fig. 1 B) . The quality of the in situ hybridization in Eurexpress is high but not always consistent. The Eurexpress Project reports that 18% of genes tested were not detected at 14.5 dpc. Whether this is due to ineffective probe design, the experimental conditions, or the gene not being expressed in the 14.5 dpc embryo is unknown. Therefore, a negative result does not necessarily mean that a gene is not expressed in vivo ; false negatives cannot be excluded . In our experience, among all the genes annotated in the testis, 83% of the in situ hybridization results with annotated testis expression were considered 'publication quality' (see Using Databases as a Discovery Tool to Construct a Genes-Of-Interest List for Testis Development). However, in some cases we found that expression was often detected even though it was not annotated. If the structure of interest is not annotated as 'expressed' or the assay is classified as 'not detected', we recommend the readers to look through the entire slide deck.
Eurexpress and other expression databases allow basic and advanced queries based on annotated anatomy, gene name, gene symbol, template, and gene sequence. Entries in the Eurexpress database are linked to other databases, such as ABA [Lein et al., 2007; Jones et al., 2009] , EMAGE [Ringwald et al., 1994; Christiansen et al., 2006] , and GENSAT [Gong et al., 2003] , and to informational resources such as Entrez Gene (https://www.ncbi.nlm.nih. gov/gene/), ENSEMBL (http://useast.ensembl.org/index. html), and MGI. The key drawback of these atlases is the lack of the ability to process a batch of genes generated by approaches such as microarrays and RNA-seq. The lack of an option to do bulk queries on a gene list, instead of on individual genes, in many of these databases means that the biologist has to manually go through digital slide decks for each gene to find the structures of interest. Although structures typically occur in the same 3-5 slice window of the 24 slice slide deck, each slice image must then be manually downloaded at high resolution and be processed. Currently, the most efficient way of examining batches of genes within most expression databases is to automatically extract information from the webpage rather than displaying it to the investigator using a third party program. This way the queried image files for each gene can be downloaded as a batch, and the images can then be scrolled through on a host computer. The introduction of a tool that allows the users to submit lists of genes and return batch searches within the database will make accessing the information stored within expression databases far easier and increase the utility of expression databases for biologists. Until this kind of tool is implemented, the investigator has 2 choices: (1) harvest/extract the image files from the database website by writing an automation script, or (2) go through the browser manually. Even if the investigator chooses the more laborious manual approach, there is great value to be gained from trawling through expression atlases.
Transcriptomic Databases (for Non-Bioinformaticians)
The abundance of transcriptomic data stored in the Gene Expression Omnibus (GEO, a public functional ge- nomics data repository) provides many opportunities for the investigator. However, many biologists do not have the programming skills to exploit this resource. Luckily, there are some useful databases that can assist the biologist querying transcriptomic data. Transcriptomic microarray data covering various stages of gonad development and a variety of enriched cell types has been generated by a number of groups [Jameson et al., 2012; McClelland et al., 2015; Inoue et al., 2016] . These data complement the spatiotemporal expression data in databases like Eurexpress. It is now standard for all the raw data for these types of studies to be deposited in GEO, so they are available for reanalysis. However, mining published transcriptomic data (such as microarray and RNAseq) can be challenging without appropriate analysis frameworks. Many 'at the bench researchers' lack the expertise to extensively mine the RNA-seq and microarray data stored in GEO. This means researchers are not able to fully utilize published data in their field.
To use data from primary archives, a certain level of expertise is needed. Raw or processed data must be downloaded, and then the data can be analyzed independently or in combination with other data. For microarray data many biologists have some expertise in using software programs such as Partek to analyze and reanalyze data from CEL files; however, RNA-seq data are more complicated to analyze. Added-value databases make the biological content of the expression data more accessible to non-bioinformaticians. These tools aggregate data stored in repositories such as GEO by extracting relevant information from the raw primary data and therefore allow the user to ask biological questions through a user-friendly interface. For example, the user can determine in which samples their gene-of-interest is expressed or which genes are differentially expressed between the 2 samples without having to handle the raw data directly.
One of the key added-value aggregators of transcriptomic information is the Gene Expression Atlas (http:// www.ebi.ac.uk/gxa) [Kapushesky et al., 2009] , which provides information about gene expression in different cell types and organs in addition to different developmental stages, disease states, and biological/experimental conditions. This atlas contains expression data from a large number of species including all common model organisms. The user can query individual genes, looking for differential gene expression by gene names or by searching for genes correlated with an attribute such as cell types. For example, Sox9/SOX9 expression can be queried in a general (to pull up all available species) or in a specific species ( Fig. 1 C, D) . In mouse, expression data are available for a variety of embryonic and adult stages from the FANTOM 49 Consortium project and other individual projects. Examining expression in the testis reveals expression during embryonic development, specifically at E16 or 16.5 dpc in the testis, pancreas, kidney, and other organs (purple in Figure 1 C) . In human, expression data are available for a number of Consortiums, including FANTOM 68, which examines expression in adult tissues. SOX9 is expressed in the testis, skin, and a number of distinct brain regions (purple in Figure 1 D ).
Pathway Analysis: GO Term Enrichment Analysis
Pathway analysis is one of the most biologist-accessible ways to look for patterns in candidate gene lists. Many similar publicly available analysis software and tools that were developed in the early 2000s can be used to function- Overview and examples of gene entries in the Eurexpress, Gene Expression Atlas, and OMIM databases. A In situ hybridization images of 14.5 dpc embryos are compiled in the Eurexpress Transcriptome Atlas Database for Mouse Embryo. Expression observed in an image is annotated and encoded as text that can be queried. The more general anatomical terms branch into more specific terms. For example, the nested terms that describe the testis are displayed. B The Eurexpress viewer scrolls through sections in a 'virtual embryo environment' and zooms into regions similar to a digital microscope. For the gene Star, the testis can be visualized in the 6th section. The testis region is demarcated by a dashed line. a, adrenal; k, kidney; m, mesonephros. C , D The Gene Expression Atlas houses easy to access transcriptomic data for a wide variety of species from all major consortia and sequencing efforts. For the gene Sox9, detailed information is available on expression in the mouse ( C ) and human ( D ). Data is presented in a tabular format that can be sorted using a number of parameters (graphics shown here are part of the full table). Selecting data from a project in the table, such as 16.5 dpc 49 FANTOM ( C ) or 68 FANTOM ( D ), highlights the organs (in our case, the testis) that are included in that dataset in purple on the interactive body map. E The OMIM database catalogues human disease variants. Entries can be either by phenotype or gene. In the example of a search for the gene NR5A1 (also known as SF1 ), there are many alternative gene symbols that have been used historically. However, the disease information is catalogued under the HUGO approved symbol ( NR5A1 ). Information on the location of the gene and all phenotypes caused by mutations in NR5A1 are listed in a table with ID numbers for each phenotype and additional information on inheritance. The entry number and mapping key encode additional information about the disorder.
ally analyze large genes-of-interest lists [Huang et al., 2009b; Khatri et al., 2012] . However, many of these databases are no longer fully updated and maintained. For this reason, out of the freely available tools we recommend DAVID (Database for Annotation, Visualization and Integrated Discover; https://david.ncifcrf.gov/) ( Table 1 ) [Huang et al., 2007 [Huang et al., , 2009b and GSEA (Gene Set Enrichment Analysis; http://software.broadinstitute.org/gsea/ index.jsp) ( Table 1 ) [Subramanian et al., 2005] . DAVID v6.8 is now available with an updated knowledgebase. v6.7 will be available for continued use until January 15, 2017 (data here is analyzed in v6.8Beta). GSEA and DA-VID use the same core approach of searching a genes-ofinterest list and then systematically map the list against a bank of GO terms in order to identify the most overrepresented or enriched terms out of all the linked terms that associate with the genes on the list. This kind of enrichment analysis strategy allows investigators to identify biological patterns and processes that may be relevant to their area of study that would never be discovered by looking at the list with the naked eye. Knowledgebases, such as DAVID and GSEA, draw on different repositories (including NCBI, https://www.ncbi.nlm.nih.gov/) and UniProt (http://www.uniprot.org/)), therefore hosting multiple GO terms for a single gene in an attempt to increase the comprehensiveness of the query output. A single gene can be mapped to many different and redundant terms, just as a single term maps to many genes. DAVID deals with this GO term redundancy by clustering and classifying the redundant terms into themed 'annotation clusters' that can be searched by the user.
When submitting a query to a pathway analysis tool, the lists of genes can be in a number of formats. DAVID's flexible input allows for a broad range of identifiers to be used as initial search criteria. However, it is recommended that unique universal gene identifiers are used as inputs so that redundant gene names are not confused. GSEA also has a series of curated gene lists that cover a curated range of gene sets drawn from chemical and genetic perturbation experiments from PubMed, in addition to genes that share conserved cis-regulatory motifs [Xie et al., 2005] and transcription factor targets (using TRANSFAC, BioBase licensed through Qiagen; http:// www.gene-regulation.com/pub/databases.html) [Wingender et al., 2000; Matys et al., 2003] . In both GSEA and DAVID the output or results of the search can be viewed and exported in a variety of ways. Be aware that these tools will restart to the main page after a period of inactivity, regardless of which step the analysis is paused at (you can set the timeout in GSEA, but for DAVID it is automatically set at 20 min inactivity). Both tools have features that link pathways and genes to disease associations, in addition to more protein-based tools that highlight protein functional domains and motifs.
For enrichment analysis, it is important to remember that size matters: a larger gene list generally results in higher statistical confidence and more significant p values in lowly enriched terms and more specific ontological terms at the ends of the ontological branches. Conversely, the broader and more general ontological terms are less enriched. The effect of list size on the absolute enrichment p values means that it is not recommended that the users directly compare the absolute enrichment p values across gene lists [Huang et al., 2009b] . In cases where well under 100 genes are in the genes-of-interest list, tools like DAVID can still be used. But using the statistical p values as metrics of significance must be used cautiously, as the statistical power behind the enrichment analysis is limited by the small number of genes [Huang et al., 2009a] . Searching such a small list will produce a very focused list of ontologies and annotations that can be thoroughly explored by the user; however, the statistics produced by the software are largely meaningless.
The basis of enrichment analysis is that there are differences between the biological processes in an abnormal or perturbed state (or in the case of developmental biology often a different cell type or time-point or genotype). The assumption is that the co-functioning genes (or related genes, which can be determined by looking at GO terms) should be enriched together and that these terms will therefore be selected as a relevant or significant group [Huang et al., 2007 [Huang et al., , 2009a Huang and Yao, 2010] . The degree of enrichment depends on the background of gene expression or the noise. The background is a key factor that can influence the conclusions drawn from the data and the certainty with which we can say genes are enriched [Huang et al., 2009a] . The background must be set up to perform the comparison in tools such as DAVID and should be carefully considered. The background gene set for analysis should only include the genes that have a chance of being selected. For this reason, choosing the whole genome when the whole genome is not represented on the Affymetrix Chip can skew the data. Similarly, when analyzing RNA-seq data, including all genes in the genome instead of discarding those genes for which no counts were recorded will skew the data [Huang et al., 2009a] . Carefully selecting a background should be a priority for each study. Customized chip background lists are available for all commonly used microarray platforms, and individualized background lists can be easily imported to meet the user's individual needs.
Mouse Knockout Databases
In order to build a comprehensive functional catalogue of the mammalian genome, a collaboration was launched to create a comprehensive library of knockout/ conditional allele mouse models for researchers to utilize. In mice, this project has been spearheaded by the International Knockout Mouse Consortium (IKMC; https:// www.mousephenotype.org/) [Bradley et al., 2012] ). The aim of IKMC is to generate targeted embryonic stem (ES) cells of all known protein-coding genes in mice and companion Cre driver lines [Rosen et al., 2015] . The current design used for targeting vectors allows for the production of reporter, conditional, and knockout alleles and provides researchers with flexibility in the design of their experiments and the ability to complement CRISPR/Cas9 strategies [Rosen et al., 2015] . The International Mouse Phenotyping Consortium (IMPC; www.knockoutmouse. org) [Ring et al., 2015] builds on the work of the IKMC to generate the mouse strains and perform standardized phenotyping. The production of mouse strains from these ES cells is tracked, and this information is freely available to the research community. The IKMC/IMPC web portals were merged to create a central hub (http:// www.mousephenotype.org) [Rosen et al., 2015] that has detailed information about the available resources including a catalogue of the targeting vectors, targeted alleles, ES cell clones, and mutant mouse strains generated and links out to other repositories. All gene trap alleles are housed at Jax (http://www.informatics. jax.org/allele). In addition, the International Mouse Strain Resource (IMSR; www.findmice.org) [Eppig, and Strivens, 1999; Eppig et al., 2015] has a searchable catalogue of over 2,000 Cre strains produced by the scientific community that links to the MGD and the repository holding the material.
At least 30% of the targeted knockouts generated in mouse by programs such as the IKMC and IMPC result in embryonic or perinatal death . This led to the inception of the Wellcome Trust-funded research program Deciphering the Mechanisms of Developmental Disorders (DMDD; https://dmdd.org.uk) [Mohun et al., 2013; Adams et al., 2013; Wilson et al., 2016] that aims to characterize these lethal mutants further. DMDD focuses on phenotyping embryonic lethal mutants to shed light on the genetic regulation of tissue differentiation, organ formation, and embryo morphogenesis . This resource is designed for developmental biologists and clinicians. It also complements existing United Kingdom clinical programs focused on better understanding low frequency and rare genetic changes leading to human disease, such as the Deciphering Developmental Disorders (https://www.ddduk. org) and UK10K (http://www.uk10k.org) projects.
Human Disease Variant Databases
Online Mendelian Inheritance in Man (OMIM; http:// www.omim.org/) [Hamosh et al., 2005; Amberger et al., 2009 Amberger et al., , 2011 ] is a resource, published since the 1960s, aimed at cataloguing known human disease variants and improving disease classification with a focus on diseases that have a significant genetic basis. One of the goals of OMIM is to develop a standard nomenclature for features of a disorder (traits) through the Human Phenotype Ontology [Amberger et al., 2011] . OMIM is a curated resource based exclusively on the biomedical literature. The database links to genomic databases and model organism information, as well as other clinical resources. OMIM serves both molecular biologists and healthcare providers by classifying disorders and biological variation reported in the literature [Amberger et al., 2011] . Entries in OMIM can be classified under the phenotype or the gene. For example, the gene NR5A1 (also known as SF1 ), is located on chromosome 9q33.3 ( Fig. 1 E) . Mutations in this gene result in 4 known phenotypes: 46,XY sex reversal, premature ovarian failure, spermatogenic failure, and adrenocortical insufficiency ( Fig. 1 E) . The allelic variants associated with each phenotype listed for a gene are briefly described under the gene entry. More detailed information about the disorder is provided in a separate descriptive entry corresponding to the phenotype (not a unique locus), and this entry has a separate identifier. The entry number and mapping key encode additional information about the disorder. More information about the assignment of different MIM numbers can be found at http:// www.omim.org/help/faq.
OMIM now facilitates a series of more advanced search options, such as retrieval of similar concepts, clinical or anatomical features. Currently, the user is still restricted to querying a single gene at a time through the OMIM interface. However, OMIM does actively encourage the large-scale mining of its repository. API (Application Program Interface) access to the entire OMIM repository (updated nightly) is freely accessible for individual research use with a reasonable fair-use license signed upon download (https://omim.org/api/). Once downloaded, tools such as 'R' can be used to query batches of genes using gene names. For example, users can query all the genes on their genes-of-interest list against the OMIM 13 database and pull out features such as the gene name, MIM number, and OMIM description into a searchable Excel file. The OMIM descriptions can then be searched as a batch for pathologies and disorders of interest.
The Human Gene Mutation Database (HGMD) represents the other comprehensive collection of mutations that underlie or are associated with human inherited diseases. From its inception the HGMD (which is run out of Cardiff University, Cardiff, UK) was part of a commercial agreement, meaning it runs 2 versions. The online HGMD version that is 'free' for academics (http://www.hgmd. cf.ac.uk/ac/index.php) [Cooper et al., 2006; Stenson et al., 2009 ] is available via the Cardiff University, and a licensed version of the database, 'HGMD Professional' ( Table 1 ) is available through Qiagen. Newly added mutational information is available to paid users for 2.5 years from the date of initial inclusion in the database before it can be accessed in the free academic resource [Stenson et al., 2009] . Therefore, we recommend using OMIM if you do not have access to the HGMD Professional version of the database.
Using Databases as a Discovery Tool to Construct a Genes-Of-Interest List for Testis Development
In addition to interrogate genes-of-interest lists, databases can also be used as a discovery tool to identify new candidate genes. By querying annotated testis expressed genes generated by the Eurexpress expression screen, we identified a pseudo-candidate list with genes expressed in the testis at 14.5 dpc. This list contains 298 entries with 289 protein-coding genes, 6 unannotated transcripts, and 3 microRNAs (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000455113). Among the 289 annotated protein-encoding genes, 34 of them are still listed under Rik ID numbers (numbered genes ending with 'Rik' are annotated genes without a canonical name yet) although the gene has subsequently been renamed. To ensure the remaining 255 genes are listed under the current approved gene names, we ran them through the HGNC (HUGO Gene Nomenclature Committee) Multi-Symbol Checker (http://www.genenames.org/cgi-bin/symbol_checker). This tool checks all the names in the submitted list against HUGO verified names and their known synonyms but does not crossreference Rik IDs. We therefore cross-referenced the 34 genes under Rik IDs in the MGI database to locate the current gene identifier (online suppl. Table 1 ). As many of the databases began cataloguing entries over 15 years ago, not all genes are listed under the current HUGO approved name. This means that the investigator may overlook entries that remain curated under defunct synonyms of IDs. Once we confirmed/identified the gene names for all 295 genes (289 protein-encoding genes and 6 unannotated transcripts), we obtained the in situ hybridization images and scored them on an arbitrary metric of 1-4 (1 = very high publication quality; 2 = high publication quality; 3 = moderate quality (requires confirmation); 4 = low quality (not publication quality)). For every gene that scored a 1 or 2 (142 genes; online suppl. Table 2 ), we downloaded a representative full embryo image containing the testis and cropped a 600 × 600 pixel section containing the testis in Photoshop. In most cases the first testis of the pair appeared in slice 3-7 of the slide deck (before the kidney), whereas the second testis appeared between slice 11-21 (after the kidney).
We first identified previously described marker genes and validated their expression. We compared the list of 289 protein-encoding genes and 6 unannotated transcripts (a total of 295) from the Eurexpress database to published microarray data for the genes enriched in 5 key testicular cell types (supporting or Sertoli cells, germ cells, interstitial cells, Leydig cells, and endothelial cells; online suppl. Table 3 ) at 13.5 dpc [Jameson et al., 2012] . For the supporting or Sertoli cell-enriched genes, among 295 testis-expressing genes from the Eurexpress database and 491 genes from the Sertoli cell-enriched genes from the Jameson et al. [2012] microarray, 35 genes were found in both datasets ( Fig. 2 A) , including 5 known Sertoli cell genes Amh, Ptgds, Etv5, Tyro3, and Col9a3 ( Fig. 2 B) . Sixteen of the 35 genes were of publication quality ( Fig. 2 C) . For the male germ cell genes, 25 genes were shared by both the Eurexpress database and the Jameson et al. Sertoli cell-expressed genes identified from testis-annotated entries in the Eurexpress database. A The list of 295 entries annotated as testis-expressed in the Eurexpress database were compared to 491 Sertoli cell-expressed genes from a microarray of sorted cells at 13.5 dpc [Jameson et. al., 2012] . A total of 35 genes were represented in both sources (online suppl. Table 2 ). B Out of these 35 genes, 5 known Sertoli cell marker genes were identified: Amh, Col9a3, Etv5, Ptgds, and Tyro3. C Sixteen novel Sertoli cell candidate genes with a quality ranking of 1 or 2 were annotated in the Eurexpress database: Adamts16, Atp8b2, Ctnna2, Cxadr, Dsp, Gjb2, Gstm7, Lsr, Npr1, Pgpep1, Slc20a1, Slc38a1, Tesc, Tmcc3, Tpd52, and Trank1 . The testis region is demarcated by a dashed line. a, adrenal; k, kidney; m, mesonephros. Scale bar, 0.5 mm. ( Fig. 3 A) , including Sox2 , Dazl, and Dppa3 ( Fig. 3 B) . Among the 25 genes, 10 were of publication quality in situ hybridization images from the Eurexpress database ( Fig. 3 C) .
The testis interstitium houses heterogeneous populations of cells including vasculature, steroidogenic fetal Leydig cells, and non-steroidogenic interstitial cells. In the Jameson et al. [2012] microarray, a Mafb -eGFP line was used to isolate both steroidogenic and non-steroidogenic interstitial cells and an Flk -mCherry line was used to isolate endothelial cells. However, expression of steroidogenic Leydig cell genes was found in cells isolated from both these lines. As a result, a mixed interstitial cell list without steroidogenic genes and a steroidogenic Leydig cell list were generated by the authors. Of the 130 mixed interstitial cell genes identified in the Jameson et al. [2012] microarray, 9 genes were also represented in the Eurexpress database ( Fig. 4 A) . In addition to 4 publication quality in situ hybridization images for known interstitial marker genes ( Fig. 4 B) , we identified images for 5 of the 9 overlapping interstitial cell genes ( Fig. 4 C) . RNAseq data on sorted nonsteroidogenic interstitial cells and fetal Leydig cells at 12.5 dpc suggests that the expression of 3 of these genes ( Clca1, Itga9, and Nrg1 ) may be in fetal Leydig cells [McClelland et al., 2015] . The Jameson et al.
[2012] microarray produced a list of Leydig cell-specific genes, 11 of which were also represented in the Eurexpress database ( Fig. 4 D) , and 8 of them are of publication quality ( Fig. 4 E) .
In addition to verifying microarray and other transcriptomic data, the data from expression atlases can be used to identify novel putative markers of the different cell lineages. The resolution of the Eurexpress images is sufficient for characterizing the subdivision of organs or mapping regional differences within structurally complex organs [Diez-Roux et al., 2011; Yang and Chen, 2014; McClelland et al., 2015] . We subsequently examined the images with a quality score of a 1 or 2 that were not represented in the Jameson et al. [2012] microarray and categorized them based on testis structures. Inside the testis cords, we found 28 genes with putative Sertoli cell expression and 24 genes with putative expression in germ cells. Twenty-six genes were found in the interstitium, 9 genes were expressed in the entire testis, and 3 genes were expressed putatively in the vasculature. For the genes expressed in the testis cords, we could not determine with certainty whether the expression was localized to the Sertoli cells or the germ cells. Likewise, interstitiumexpressed genes could be expressed in the fetal Leydig cells or in nonsteroidogenic interstitial cells.
This list of candidate genes (295 genes) can be considered as a small randomized data set similar to an experiment examining the expression patterns of genes in a 14.5 dpc testis. As a first pass for the following pathway analysis, we used the 'Tissue Expression' feature in DAVID to get a quick look at a list of reported expression patterns in different tissues for each gene [Huang et al., 2009a] . Using this tool we were able to interrogate expression patterns of 162 genes, and we determined that 55 genes had expression reported in the fetal or adult testis (online suppl. Table 4 ). We then queried the complete list of genes in DAVID (V6.8Beta) to search for enriched associations among these genes. As expected, because this gene list was randomly assembled, not a complete representation of gene expression at 14.5 dpc and not directly testing a hypothesis, there were few strongly enriched processes or pathways. Subsequently, as an example, we performed pathway enrichment analysis on the list of 289 protein-encoding genes to look for enriched clusters, and identified an overrepresentation of genes involved in glutathione metabolism (6 genes) and transcriptional regulation (39 genes) in the gene list (online suppl. Table 5) . When looking at a newly generated gene list, an initial submission to DAVID after validating expression of a few genes on the list can provide directions for specific niche searches. Once a pathway or process is identified as being enriched using DAVID, expression of other pathway components can be validated using expression databases and transcriptomic resources. These pathways can then be queried in OMIM to look for an association with human diseases. For example, from RNA-seq data profiling the interstitial cells of the fetal testis, 'neuroactive ligand Fig. 3 . Germ cell-expressed genes identified from testis-annotated entries in the Eurexpress database. A The list of 295 entries annotated as testis-expressed in the Eurexpress database were compared to 433 germ cell-expressed genes from a microarray of sorted cells at 13.5 dpc [Jameson et. al., 2012] . A total of 25 genes were represented in both sources (online suppl. Table 2 ). B These genes included the known germ cell markers Sox2 and Dppa3. The germ cell marker Dazl was also included as a positive control. C In the Eurexpress database, there were 10 novel germ cell genes that were also represented in the microarray: Ap3b2, Bub1, Cdk5rap1, Irf1, Liph, Mybbp1a, Rcc2, Rcl1, Trip13, and interaction' is overrepresented by analysis using DAVID. By identifying the receptor/ligand pairs in different testicular cell populations, a putative model could be constructed. Several components of this model had a known association with DSD [Diez-Roux et al., 2011; McClelland et al., 2015] . By reconstructing the pathways in silico, expression of the gene Frem2/FREM2 (Fras1 related extracellular matrix protein 2) and its family member Fras1 (Fraser syndrome 1 homolog), known DSD genes (OMIM:219000), were identified in the developing gonad [Jadeja et al., 2005; McClelland et al., 2015] .
Tools like DAVID rely on querying what is known about the function of a gene. As a result, although powerful in uncovering functionality, this approach cannot make inferences or uncover unknown functionality. This limitation is illustrated by the example of Pdgfa ( platelet-derived growth factor-alpha) , which encodes the PDGF-A and is annotated in GO for the molecular function of platelet-derived growth factor receptor binding. However, although it is annotated for the biological processes of lung alveolar development (GO:0048286), salivary gland morphogenesis (GO:0060683), and bone development (GO:0060348; among others), it is not annotated for the biological process of male gonad development (GO:0008584). To a researcher in the field of sex determination and germ cell development, it may be obvious that Pdgfa should be involved in male gonad development, as we know this pathway is important for gonadogenesis [Brennan et al., 2003; Schmahl et al., 2008; Cool et al., 2011] . However without appropriate annotation for this biological process, the program cannot computationally retrieve Pdgfa as associated with testicular development. The tool is only as complete and up-to-date as the GO terms it uses.
The Power of Annotation: The Case of the Missing Ovary
If 298 entries are annotated as expressed in the testis in the Eurexpress database, we would assume that the same discovery capacity should be found in querying the ovary.
When queried under the anatomy search for 'ovary', only 28 entries were retrieved. These numbers of genes are far less than the numbers of genes catalogued from the microarray data [Nef et al., 2005; Liu et al., 2010; Jameson et al., 2012] . We have discussed that many genes are annotated in several biological processes, yet we know that some biological processes are better studied than others. This should be a consideration when interpreting query results relying on GO terms, as some processes and gene families are more thoroughly annotated than the others largely due to historical reasons or the size of the research field. Similarly, the expression of genes annotated in some organs, for example the ovary, depends on semi-experts being able to accurately identify an organ in a tissue section [DiezRoux et al., 2011] . In the 298 entries annotated for the testis, 11 (3.7%) genes were annotated incorrectly, where expression was actually in the neighboring pancreas or kidney. In an organ like the ovary, which does not develop apparent distinguishing features like testis cords, it is a lack of annotation in databases that hampers researchers, rather than a lack of expression of ovarian genes.
In some cases, a lack of annotation can become a serious problem that skews the results. All GO terms tend to be weighted equally in enrichment tools, whereas in reality certain ontologies are better described than others [Huang et al., 2009b] . This is often more of a problem in emerging or smaller fields. A better described ontology, based on gene families or specific processes where there is more available data, tends to have a higher chance of being associated with any list. The search is only as good as the ontology and the annotation behind it.
Conclusion
We are surrounded by transcriptomic data telling us what genes go up and what genes go down. Thanks to the affordability of transcriptomics, we have more data than we could have ever imaged. Each microarray or RNA-seq experiment produces an extensive list of candidate genes. What we have not had is a way to prioritize the genes on Interstitial and fetal Leydig cell-expressed genes identified from testis-annotated entries in the Eurexpress database. A The list of 295 entries annotated as testis-expressed in the Eurexpress database were compared to 130 interstitial cell-expressed genes from a microarray of sorted cells at 13.5 dpc [Jameson et al., 2012] . A total of 9 genes were represented in both sources (online suppl. Table 2 ). B Among these genes, 4 known interstitial/Leydig cell marker genes were identified: Cyp11a1, Prlr, Star, and Tacr3.
C High-quality in situ hybridization images were available for 5 of the 9 overlapping interstitial genes: Clca1, Cxcl12, Itga9, Nrg1, and Sostdc1. D Eleven genes were represented in both the Leydig cell microarray and the Eurexpress database (online suppl. Table 2 ). E High-quality in situ hybridization images were available for 8 genes: Fads1, Gramd1b, Hsd17b7, Prkar2b, Ren1, Scarb1, Sct, and Stc1 . The testis region is demarcated by a dashed line. a, adrenal; k, kidney; m, mesonephros. Scale bar, 0.5 mm.
with human disease. So, before you decide to a make a genetically modified mouse, sit down at your desk and put the other type of mouse to work.
